F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

A Food and Drug Administration panel has voted to endorse the broader use of peptides in compounding pharmacies. This decision has raised concerns about a potential prescribing boom, as compounding pharmacies have grown into a multibillion-dollar business with relatively light regulation. The endorsement may lead to increased availability and use of peptides, which could have significant implications for public health. Critics are warning about the potential risks associated with the expanded use of these peptides.

✦ AI-generated summary